FRZB and neoplasm: As shown in Figure 2A-F, FRZB expression wassignificantly down-regulated in different subgroups of HNSCC patients, includingTP53 mutation status, HPV status, metastasis,gender, and tumor grade and stage,indicating that FRZB may be a potential biomarker for patients with HNSCC.